Literature DB >> 16388906

PLGA-microsphere mediated clearance of bilirubin in temporarily hyperbilirubinemic rats: an alternate strategy for the treatment of experimental jaundice.

N Ahmad1, K Arif, S M Faisal, M K Neyaz, S Tayyab, M Owais.   

Abstract

In the present study, we have demonstrated the suitability of microspheres in removal of plasma bilirubin from systemic circulation of hyperbilirubinemic rats. Poly (lactide co-glycolide) microspheres (PLGA microspheres) have been shown to bind with bilirubin in both a concentration and time dependent manner. The binding affinity of bilirubin to microspheres was enhanced when rat serum albumin (RSA) was loaded into the microspheres. On evaluating the potential of microspheres in elimination of bilirubin from the systemic circulation, RSA bearing microspheres were found to be competent in both removing bilirubin from the systemic circulation and controlling elevated plasma levels of liver function enzymes in temporarily hyperbilirubinemic rats. On the basis of results of the present study, we suggest that microsphere-based delivery system may help in development of safe, effective and alternate strategy for the treatment of hyperbilirubinemic conditions in model animals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16388906     DOI: 10.1016/j.bbagen.2005.11.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  2 in total

1.  Effect of interstitial chemotherapy with ricin temperature-responsive gel for anti-breast cancer and immune regulation in rats.

Authors:  Zhi-Kui Chen; Li-Wu Lin; Jing Cai; Fa-Duan Yang; Hua-Jing Cai; En-Sheng Xue; Jing Huang; Hong-Fen Wei; Xiu-Juan Zhang
Journal:  Chin J Integr Med       Date:  2011-06-29       Impact factor: 1.978

2.  US-guided interstitial chemotherapy using paclitaxel temperature-responsive gel for breast cancer treatment in rat.

Authors:  Zhi-kui Chen; Li-wu Lin; Ying-hong Yang; Hua-jing Cai; Jia-jia Yang; Min-xian Cai
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-24       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.